These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12269846)

  • 1. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.
    Podar T; Tuomilehto J
    Drugs; 2002; 62(14):2007-12. PubMed ID: 12269846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Inquiry: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?
    Trietley GS; Wilson SA; Chaudhri P; Payette N; Higbea A; Nashelsky J
    J Fam Pract; 2017 Apr; 66(4):257-263. PubMed ID: 28375400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of anti-hypertensive agents in diabetic subjects.
    Patel BM; Mehta AA
    Diab Vasc Dis Res; 2013 Sep; 10(5):385-96. PubMed ID: 23811601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
    Giles TD; Sander GE
    Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of angiotensin II receptor antagonists in the management of diabetes.
    Barnett AH
    Blood Press Suppl; 2001; 1():21-6. PubMed ID: 11333010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of hypertension complicating diabetes mellitus.
    MacLeod MJ; McLay J
    Drugs; 1998 Aug; 56(2):189-202. PubMed ID: 9711444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of angiotensin II antagonists in the treatment of hypertension].
    Gerc V
    Med Arh; 2002; 56(3):167-73. PubMed ID: 12378864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions.
    Moser M
    J Am Coll Cardiol; 1997 Jun; 29(7):1414-21. PubMed ID: 9180098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus.
    Harel Z; Silver SA
    Evid Based Med; 2014 Dec; 19(6):218. PubMed ID: 25165155
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicinal chemistry of drugs used in diabetic cardiomyopathy.
    Adeghate E; Kalasz H; Veress G; Teke K
    Curr Med Chem; 2010; 17(6):517-51. PubMed ID: 20015035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.